Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
MEDIPHARMA from Boortmeerbeek, company number BE0821792314, closed financial year 2025 with a result of € 94,281 after tax. For that financial year MEDIPHARMA recorded a gross margin of € 149,772 and equity of € 2 million. Compared with financial year 2024, the result moved from € 149,317 to € 94,281. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 15, 2026.
€ 2 million
▲ 5% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 94,281
▼ 37% vs 2024
Profit after tax over the fiscal year.
€ 1,830
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 2 million.
Debts at end 2025
€ 208,549
▼ 27% vs 2024
€ 81,427 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 4,187
Supplier invoices still open on the last day of the fiscal year.
€ 14,232
▼ 14% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 212,968 | € 276,674 | € 239,133 | € 149,772 | ▼ 37% |
| Profit after taxes | € 128,163 | € 173,565 | € 149,317 | € 94,281 | ▼ 37% |
| Equity | € 1,630,091 | € 1,803,656 | € 1,952,974 | € 2,047,255 | ▲ 5% |
| Total debts | € 1,099,209 | € 911,065 | € 751,081 | € 661,087 | ▼ 12% |
| Cash | € 1,923 | € 3,722 | - | € 1,830 | |
| Retained profit | € 1,617,691 | € 1,791,256 | € 1,940,574 | € 2,034,855 | ▲ 5% |
| Bank debt | € 641,173 | € 491,173 | € 284,540 | € 208,549 | ▼ 27% |
| Balance sheet total | € 2,729,300 | € 2,714,721 | € 2,704,055 | € 2,708,342 |
Key figures of MEDIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDIPHARMA?
What happened at MEDIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 94,281 (▼ 37% vs 2024). Source: NBB ↗
- New establishment in Boortmeerbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 128,163 profit in 2022 to € 94,281 profit in 2025.
Paid € 193,982 in corporate taxes since 2022.
Best year ever: 2023, with € 173,565 profit.
Management
Behind MEDIPHARMA are Ann Hendrix and Antoon Medaer. It owns 100% of Pharmapoint itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Leuvensesteenweg 22
3191 Boortmeerbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0821.792.314
- VAT number
- BE 0821.792.314
- Registered office
- Leuvensesteenweg 22, 3191 Boortmeerbeek
- Names & denominations
- MEDIPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 December 2009
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Activiteiten van holdings
Holdings